General introduction:

 

Raviset® vaginal suppositories and tablets represent a true breakthrough in the treatment of menorrhagia and excessive postpartum bleeding. This innovative drug has therapeutic properties that no other drug can offer. Raviset shortens the bleeding period while reducing the associated pain.  The Company strongly believes that this product will be rapidly accepted by the Eastern European Countries and from their to the rest of the world’s markets. To insure fast market acceptance, the Company will conduct advertisement campaigns and develop market education programs targeted at gynecologist and Delivery Hospitals physicians.

 

•Package contains 6 units /box. 

 

 

 

 

 

 

 

 

 

Vaginal Raviset® tablets -

 contains 100 mg. of S-Ethyl-isothiouronium Diethyl-phosphate each tablet.

 Indicated for menorrhagia and excessive postpartum bleeding and pain syndrome, will be sold as 8 tablets in a blister and one intra vaginal applicator.

 

 

 

 

 

 

 

 

 

 

 

 

Current status & advantages:

Only one of its kind - exclusive drug compound

A pharmaceutical solution to medical problem

Big demand

Two preliminary efficacy clinical trials conducted with positive results

Registered in Moldova.

 

Market for Menorrhagia / Postpartum hemorrhaging

 

Raviset®, Intra-vaginal suppositories and tablets for excessive bleeding disorders and reducing the pain associated with this phenomena.

 

 

Summary:

Raviset® in both formulations as suppositories and vaginal tablets is a new drug with unique mechanism of action. The indication is known as one with out clinical remedy, and it addresses a big market.

The intra-vaginal tablet formulation is distinctive and found to be very effective. The women using it will find it ease to use and relatively quickly resolving the medical condition. The IP position is very strong, since this is a new application.